

(43) International Publication Date 20 October 2005 (20.10.2005)

(10) International Publication Number WO 2005/097752 A1

- (51) International Patent Classification⁷: C07D 215/56, 401/12, 401/14, A61K 31/496, 31/506, A61P 35/00
- (21) International Application Number:

PCT/US2005/010999

- (22) International Filing Date: 31 March 2005 (31.03.2005)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/558,432

31 March 2004 (31.03.2004)

- (71) Applicant (for all designated States except US): BAYER PHARMACEUTICALS CORPORATION [US/US]; 400 Morgan Lane, West Haven, CT 06516 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): KHIRE, Uday [US/US]; 411 Ridge Road, Orange, CT 06477 (US). LIU, Xiao-Gao [US/US]; 576 Central Avenue, 1A, New Haven, CT 06515 (US). NAGARATHNAM, Dhanapalan [US/US]; 52 Virginia Rail Drive, Bethany, CT 06524 (US). WOOD, Jill [US/US]; 3007 Ridge Road, North Haven, CT 06473 (US). WANG, Lei [CN/US]; 129 York Street, Apt. 8A, New Haven, CT 06511 (US). LIU, Donglei [CN/US]; 11 Bassett Street, Apt. D9, West Haven, CT 06516 (US). ZHAO, Jin [CN/US]; 333 Town Colony Drive, Middletown, CT 06457 (US). GUERNON, Leatte [US/US]; 270 Magee Drive, Hamden, CT 06514 (US). ZHANG, Lei [CN/US]; 45 Tanglewood Drive, Hamden, CT 06518 (US).
- (74) Agents: GREENMAN, Jeffrey, M. et al.; Bayer Pharmaceuticals Corporation, 400 Morgan Lane, West Haven, CT 06516 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

[Continued on next page]

(54) Title: QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDI-TIONS

$$(R^{4})_{0-2} \qquad (C(O)R^{20})$$

$$Ar \qquad R^{10} \qquad (R^{19})_{0-1} \qquad (I)$$

(57) Abstract: Quinolone carboxylic acid derivatives of formula (I) wherein Ar is an optionally substituted phenyl, pyridyl, or pyrimidinyl group and the substituent groups R1, R4, R10, R11, R19, and R20 are as defined in the specification, pharmaceutical compositions containing them, and methods of using them in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.

A1 WO 2005/097752

WO 2005/097752 A1



— of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.